A safer treatment for lung injury in premature infants
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects
This study is looking at a new inhaled medicine called ciclesonide to see if it can help improve lung health in premature babies with bronchopulmonary dysplasia while keeping their brain development safe, offering a potentially better option than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10875293 on NIH RePORTER |
What this research studies
This research investigates a new inhaled glucocorticoid, ciclesonide, to treat bronchopulmonary dysplasia (BPD) in premature infants. The study aims to determine if ciclesonide can reduce lung injury without causing harmful effects on brain development, which is a significant concern with current treatments like dexamethasone. By using a combination of laboratory and clinical approaches, the research will explore the safety and efficacy of this new treatment in neonates. The goal is to provide a safer alternative that helps improve lung function while minimizing neurological risks.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants born at or before 28 weeks of gestation who are at risk for developing bronchopulmonary dysplasia.
Not a fit: Patients who are not premature or who do not have acute lung injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer treatment option for lung injury in premature infants, reducing the risk of long-term neurological damage.
How similar studies have performed: Previous studies have shown that inhaled glucocorticoids can be effective in treating asthma without significant adverse effects, suggesting potential for success with this new approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Defranco, Donald B — University of Pittsburgh at Pittsburgh
- Study coordinator: Defranco, Donald B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.